Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,297 papers from all fields of science
Search
Sign In
Create Free Account
AG 337
Known as:
AG-337
, AG337
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (3)
Quinazolines
nolatrexed
nolatrexed dihydrochloride
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors
K. Yau
,
P. Price
,
Radhakrishma G. Pillai
,
E. Aboagye
European Journal of Nuclear Medicine and…
2006
Corpus ID: 2405254
PurposeWe recently showed an increase in tumour uptake of 2-[11C]thymidine in patients with gastrointestinal malignancies after…
Expand
Highly Cited
2003
Highly Cited
2003
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.
P. Wells
,
E. Aboagye
,
+8 authors
D. Newell
Journal of the National Cancer Institute
2003
Corpus ID: 19755363
BACKGROUND Some anticancer drugs inhibit thymidylate synthase (TS), a key enzyme for thymidine nucleotide biosynthesis. Cells can…
Expand
Highly Cited
2003
Highly Cited
2003
Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines.
H. Backus
,
D. Wouters
,
+4 authors
G. Peters
European Journal of Cancer
2003
Corpus ID: 32035550
1998
1998
Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
R. Mauritz
,
M. W. Bekkenk
,
+6 authors
Gerrit Jansen
Clinical Cancer Research
1998
Corpus ID: 30917718
Leukemic cells of 27 children [14 patients with initial acute lymphoblastic leukemia (iALL), 8 patients with relapsed ALL (rALL…
Expand
1998
1998
Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model.
M. Hu
,
K. Roland
,
+4 authors
S. Roy
Journal of Pharmacy and Science
1998
Corpus ID: 20871375
The purpose of this study was to determine the intestinal absorption characteristics of AG337, a mechanism-based inhibitor of…
Expand
1997
1997
Initial clinical trial and pharmacokinetics of ThymitaqTM (AG337) by 10-day continuous infusion in patients with advanced solid tumors
P. Creaven
,
L. Pendyala
,
+6 authors
M. Dixon
Cancer Chemotherapy and Pharmacology
1997
Corpus ID: 22380962
Purpose: To establish the maximum tolerated dose (MTD), dose-limiting and other major toxicities and the major pharmacokinetic…
Expand
Review
1997
Review
1997
Antifolates in clinical development.
C. Takimoto
Seminars in Oncology
1997
Corpus ID: 31003248
Many novel antifolate compounds with unique pharmacologic properties are currently in clinical development. These newer…
Expand
1996
1996
Modulation of [5-125I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors.
J. Mester
,
K. DeGoeij
,
M. Sluyser
European Journal of Cancer
1996
Corpus ID: 22887169
1995
1995
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride…
Rafi
,
Taylor
,
+10 authors
Newell
1995
Corpus ID: 26039813
3,4-Dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)quinazobone dihydrochboride (AG337) is a nonclassical inhibitor of…
Expand
Review
1994
Review
1994
The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor.
A. Jackman
,
R. Kimbell
,
+4 authors
F. T. Boyle
Advances in Experimental Medicine and Biology
1994
Corpus ID: 41750924
Thymidylate synthase (TS) is regarded as a good target for the development of quinazoline (folate-based) anticancer agents. The…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE